 |
|
CLINICIAN'S CORNER
Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic DysfunctionA Systematic Review
Finlay A. McAlister, MD, MSc;
Justin Ezekowitz, MBBCh, MSc;
Nicola Hooton, MPH;
Ben Vandermeer, MSc;
Carol Spooner, BScN, MSc;
Donna M. Dryden, PhD;
Richard L. Page, MD;
Mark A. Hlatky, MD, MPH;
Brian H. Rowe, MD, MSc
JAMA. 2007;297:2502-2514.
Context Left ventricular (LV) systolic dysfunction causes substantial morbidity and mortality, even with optimal pharmacotherapy. Atrial-synchronized biventricular pacemakers (cardiac resynchronization therapy [CRT]) received US Food and Drug Administration (FDA) approval for use in selected patients with LV systolic dysfunction in 2001.
Objective To summarize the current evidence base for the efficacy, effectiveness, and safety of CRT in patients with LV systolic dysfunction.
Evidence Acquisition A search of multiple electronic databases until November 2006 was supplemented by hand searches of reference lists of included studies and review articles, proceedings booklets from meetings, FDA reports, and contact with primary study authors and device manufacturers. A total of 14 randomized trials (4420 patients) were included for the CRT efficacy review, 106 studies (9209 patients) for the CRT effectiveness review, and 89 studies (9677 patients) reported safety outcomes with implantation of a CRT device.
Evidence Synthesis All patients in the CRT studies had LV systolic dysfunction (mean LV ejection fraction [LVEF] range, 21%-30%), prolonged QRS duration (mean range, 155-209 milliseconds), and 91% had New York Heart Association (NYHA) class 3 or 4 heart failure symptoms despite optimal pharmacotherapy. CRT improved LVEF (weighted mean difference, 3.0%; 95% confidence interval [CI], 0.9%-5.1%), quality of life (weighted mean reduction in Minnesota Living With Heart Failure Questionnaire, 8.0 points; 95% CI, 5.6-10.4 points), and functional status (improvements of  1 NYHA class were observed in 59% of CRT recipients in the randomized trials). CRT decreased hospitalizations by 37% (95% CI, 7%-57%), and all-cause mortality decreased by 22% (95% CI, 9%-33%). Implant success rate was 93.0% (95% CI, 92.2%-93.7%) and 0.3% of patients died during implantation (95% CI, 0.1%-0.6%). During a median 11-month follow-up, 6.6% (95% CI, 5.6%-7.4%) of CRT devices exhibited lead problems and 5% (95% CI, 4%-7%) malfunctioned.
Conclusions CRT reduces morbidity and mortality in patients with LV systolic dysfunction, prolonged QRS duration, and NYHA class 3 or 4 symptoms when combined with optimal pharmacotherapy. The incremental benefits of combined CRT plus implantable cardioverter-defibrillator devices vs CRT-alone devices in patients with LV systolic dysfunction remain uncertain.
Author Affiliations: The University of Alberta Evidence-based Practice Center, Edmonton, Alberta (Drs McAlister, Ezekowitz, Dryden, and Rowe, and Mr Vandermeer, and Mss Hooton and Spooner); Division of General Internal Medicine (Dr McAlister), Division of Cardiology (Dr Ezekowitz), and Department of Emergency Medicine (Dr Rowe), University of Alberta, Edmonton; Division of Cardiology, University of Washington School of Medicine, Seattle (Dr Page); and Department of Health Research and Policy, Stanford University, Stanford, Calif (Dr Hlatky).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Heart Failure
, , and
JAMA. ;297():2548-2548.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Is it Time to Expand the Use of Cardiac Resynchronization Therapy to Patients With Mildly Symptomatic Heart Failure?
Exner
J Am Coll Cardiol 2009;54:1847-1849.
FULL TEXT
Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008
van Veldhuisen et al.
Eur J Heart Fail 2009;0:hfp149v1-hfp149.
ABSTRACT
| FULL TEXT
Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart
Handoko et al.
Am. J. Physiol. Heart Circ. Physiol. 2009;297:H1752-H1759.
ABSTRACT
| FULL TEXT
Is cardiac resynchronization therapy cost-effective?
Boriani et al.
Europace 2009;11:v93-v97.
ABSTRACT
| FULL TEXT
Midterm 'super-response' to cardiac resynchronization therapy by biventricular pacing with fusion: insights from electro-anatomical mapping
Vatasescu et al.
Europace 2009;0:eup333v1-eup333.
ABSTRACT
| FULL TEXT
The European cardiac resynchronization therapy survey
Dickstein et al.
Eur Heart J 2009;30:2450-2460.
ABSTRACT
| FULL TEXT
MADIT-CRT -- Breathtaking or Time to Catch Our Breath?
Jessup
NEJM 2009;361:1394-1396.
FULL TEXT
Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry
Boriani et al.
Eur Heart J 2009;30:2275-2283.
ABSTRACT
| FULL TEXT
Robot-assisted cardiac surgery
Modi et al.
ICVTS 2009;9:500-505.
ABSTRACT
| FULL TEXT
Genomic Analysis of Left Ventricular Remodeling
Sarwar and Cook
Circulation 2009;120:437-444.
FULL TEXT
Echocardiography for cardiac resynchronization therapy selection: fatally flawed or misjudged?
Sanderson
J Am Coll Cardiol 2009;53:1960-1964.
ABSTRACT
| FULL TEXT
Ion Channel Subunit Expression Changes in Cardiac Purkinje Fibers: A Potential Role in Conduction Abnormalities Associated With Congestive Heart Failure
Maguy et al.
Circ. Res. 2009;104:1113-1122.
ABSTRACT
| FULL TEXT
Extraction of chronic pacemaker and defibrillator leads from the coronary sinus: laser infrequently used but required
Hamid et al.
Europace 2009;11:213-215.
ABSTRACT
| FULL TEXT
Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment.
Flaherty et al.
J Am Coll Cardiol 2009;53:254-263.
ABSTRACT
| FULL TEXT
CHAPTER 23 Heart Failure
McMurray et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT
| FULL TEXT
Does cardiac resynchronisation therapy improve survival and quality of life in patients with end-stage heart failure?
Turley et al.
ICVTS 2008;7:1141-1146.
ABSTRACT
| FULL TEXT
Cardiac Resynchronization in Patients With Atrial Fibrillation: A Meta-Analysis of Prospective Cohort Studies
Upadhyay et al.
J Am Coll Cardiol 2008;52:1239-1246.
ABSTRACT
| FULL TEXT
A case of diaphragmatic pacing with cardiac resynchronization therapy
Hamid et al.
Europace 2008;10:1229-1231.
ABSTRACT
| FULL TEXT
Contemporary Pacemakers: What the Primary Care Physician Needs to Know
Kaszala et al.
Mayo Clin Proc. 2008;83:1170-1186.
ABSTRACT
| FULL TEXT
A Critical Appraisal of Implantable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death
Tung et al.
J Am Coll Cardiol 2008;52:1111-1121.
ABSTRACT
| FULL TEXT
Cardiac Resynchronization Therapy for Heart Failure: A Hammer in Search of Nails
McAlister
Circulation 2008;118:901-903.
FULL TEXT
Use of Cardiac Resynchronization Therapy in Patients Hospitalized With Heart Failure
Piccini et al.
Circulation 2008;118:926-933.
ABSTRACT
| FULL TEXT
Ventricular optimization of biventricular pacing: a systematic review
Lim et al.
Europace 2008;10:901-906.
ABSTRACT
| FULL TEXT
Temporary pacing wire in the coronary sinus: a novel treatment of acute heart failure?
Osman et al.
Europace 2008;10:877-879.
ABSTRACT
| FULL TEXT
Update on the pathophysiological basics of cardiac resynchronization therapy
Auricchio and Prinzen
Europace 2008;10:797-800.
ABSTRACT
| FULL TEXT
Heart Inefficiency in Pulmonary Hypertension A Double Jeopardy.
Beyar
J Am Coll Cardiol 2008;51:758-759.
FULL TEXT
Device therapy in heart failure
McAlister
BMJ 2007;335:895-896.
FULL TEXT
Highlights of the 56th Annual Scientific Session of the American College of Cardiology, March 24-27, 2007. ACC.07 and i2 Summit Highlights: A Conversation With the Experts.
Tuzcu et al.
J Am Coll Cardiol 2007;50:C2-31.
FULL TEXT
|
